SEC Form 4 · accession 0001209191-17-059524
CymaBay Therapeutics, Inc. · CBAY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carl Goldfischer
Director
Period of report
Nov 2, 2017
Accepted (ET)
Nov 6, 2017 · 8:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042074
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 2, 2017 | M | 9,000 | $1.72 | A | 9,000 | D | |
| Common Stock | Nov 2, 2017 | M | 9,000 | $2.97 | A | 18,000 | D | |
| Common StockF1 | Nov 2, 2017 | S | 18,000 | $8.66 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $1.72 | Nov 2, 2017 | M | 9,000 | D | — | Jun 27, 2026 | Common Stock | 9,000 | 0 | D |
| Stock Option (right to buy)F2 | $2.97 | Nov 2, 2017 | M | 9,000 | D | — | Jun 23, 2025 | Common Stock | 9,000 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.60 to $8.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F2Fully vested.